Company

Renagade Therapeutics, Inc.

Renagade Therapeutics develops RNA medicines and delivery technologies for disease research and treatment.

About

Founded in 2021 and based in Massachusetts, Renagade Therapeutics develops RNA medicines and delivery technologies. Its toolkit supports RNA transport, coding, editing, and insertion, with applications across different disorders. In May 2023, it raised USD 300 million in Series A funding from F2 Ventures and MPM Capital to advance research and development.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in